Insider: Kovelman Harry Chief Medical Officer - MYOMO, INC.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 97,973 | 0 | 97,973 |
| Value | $89,155.43 | $0.00 | $89,155.43 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 03/12/2025 | DDS | 30,000 | Direct | COM | $5.50 | $165,018.00 | 97,973 |
| 09/05/2024 | DDS | 6,700 | Direct | COM | $3.76 | $25,182.62 | 123,556 |
| 09/03/2024 | DDS | 2,029 | Direct | COM | $4.01 | $8,140.35 | 130,395 |
| 05/15/2024 | DDS | 35,426 | Direct | COM | $3.69 | $130,838.85 | 98,009 |
| 12/01/2023 | DDS | 8,333 | Direct | COM | $0.00 | $0.00 | 140,854 |
| 08/29/2023 | AAP | 8,333 | Direct | COM | $0.60 | $4,999.80 | 149,556 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research